To access this material please log in or register

Register Authorize

Issues of etiology, pathophysiology and variants of hypertrophic cardiomyopathy course

Kaplunova V. Yu., Belenkov Yu. N., Privalova E. V., Khabarova N. V., Shakarjyants G. A., Kozhevnikova M. V.
State Budgetary Educational Institution “I. M. Sechenov First Moscow State Medical University” of the RF Ministry of Health Care, Trubetskaya 8, Bld. 2, Moscow 119991

Keywords: hypertrophic cardiomyopathy, pathogenesis, etiology

DOI: 10.18087/rhfj.2013.3.1825

Studies of hypertrophic cardiomyopathy (HCMP) are still relevant considering the high prevalence of HCMP (1:500) and the risk of sudden cardiac death (SCD) in young, able-bodied people. The issues of high interest are search for additional clinico-instrumental and genetic markers and environmental factors, which may induce formation of HCMP clinical variants, and SCD risk and prognosis in HCMP. An important issue requiring further investigation is development of a clear tactics for managing patients based on own experience or results of multicenter studies.
  1. Gersh BJ, Maron BJ, Bonow RO et al. 2011 ACCF / AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation / American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2011;58 (25):e212–260.
  2. Maron BJ, Gardin JM, Flack JM et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults: echocardiographic analysis of 4111 subjects in the CARDIA Study Coronary Artery Risk Development in (Young) Adults. Circulation. 1995;92 (4):785–789.
  3. Maron BJ, Epstein SE. Hypertrophic cardiomyopathy: a discussion of nomenclature. Am J Cardiol. 1979 Jun;43 (6):1242–1244.
  4. Maron MS, Olivotto I, Zenovich AG et al. Hypertrophic cardiomyo­pathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation. 2006;114 (21):2232–2239.
  5. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA. 2002;287 (10):1308–1320.
  6. Maron BJ, McKenna WJ, Danielson GK et al. American College of Cardiology / European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol. 2003;42 (9):1687–1713.
  7. Maron BJ, Seidman CE, Ackerman MJ et al. How should hypertrophic cardiomyopathy be classified? What’s in a name? Dilemmas in nomenclature characterizing hypertrophic cardiomyopathy and left ventricular hypertrophy. Circ Cardiovasc Genet. 2009;2 (1):81–85.
  8. Maron BJ, Yeates L, Semsarian C. Clinical challenges of genotype positive, phenotype negative family members in hypertrophic cardiomyopathy. Am J Cardiol. 2011;107 (4):604–608.
  9. Maron BJ, Semsarian C. Emergence of gene mutation carriers and the expanding disease spectrum of hypertrophic cardiomyopathy. Eur Heart J. 2010;31 (13):1551–1553.
  10. Maron MS, Maron BJ, Harrigan C et al. Hypertrophic cardiomyo­pathy phenotype revisited after 50 years with cardiovascular magnetic resonance. J Am Coll Cardiol. 2009;54 (3):220–228.
  11. Christiaans I, Lekanne dit Deprez RH, van Langen IM, Wilde AA. Ventricular fibrillation in MYH7‑related hypertrophic cardiomyo­pathy before onset of ventricular hypertrophy. Heart Rhythm. 2009;6 (9):1366–1369.
  12. Nagueh SF, McFalls J, Meyer D et al. Tissue Doppler imaging predicts the development of hypertrophic cardiomyopathy in subjects with subclinical disease. Circulation. 2003;108 (4):395–398.
  13. Klues HG, Schiffers A, Maron BJ. Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. J Am Coll Cardiol. 1995;26 (7):1699–708.
  14. Maron BJ, Gottdiener JS, Epstein SE. Patterns and significance of distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy:a wide angle, two dimensional echocardiographic study of 125 patients. Am J Cardiol. 1981;48 (3):418–428.
  15. Alcalai R, Seidman JG, Seidman CE. Genetic basis of hypertrophic cardiomyopathy: from bench to the clinics. J Cardiovasc Electrophysiol. 2008;19 (1):104–110.
  16. Arad M, Seidman CE, Seidman JG. AMP-activated protein kinase in the heart: role during health and disease. Circ Res. 2007;100 (4):474–488.
  17. Ahmad F, Seidman JG, Seidman CE. The genetic basis for cardiac remodeling. Annu Rev Genomics Hum Genet. 2005;6:185–216.
  18. Bos JM, Towbin JA, Ackerman MJ. Diagnostic, prognostic, and therapeutic implications of genetic testing for hypertrophic cardiomyopathy. J Am Coll Cardiol. 2009;54 (3):201–211.
  19. Seidman JG, Seidman C. The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell. 2001;104 (4):557–567.
  20. Wigle ED, Sasson Z, Henderson MA et al. Hypertrophic cardiomyo­pathy: the importance of the site and the extent of hypertrophy: a review. Prog Cardiovasc Dis. 1985;28 (1):1–83.
  21. Wigle ED, Rakovski H, Kimball BP, Williams WG. Hypertrophic cardiomyopathy: clinical spectrum and treatment. Circulation. 1995;92 (7):1680–1692.
  22. Braunwald E., Lambert C. T., Rockoff S. D. et al. Idiopathic hypertrophic subaortic stenosis, I: a description of the disease based upon an analysis of 64 patients. Circulation. 1964; 30 (suppl 4):119.
  23. Kim JJ, Lee CW, Park SW et al. Improvement in exercise capacity and exercise blood pressure response after transcoronary alcohol ablation therapy of septal hypertrophy in hypertrophic cardiomyo­pathy. Am J Cardiol. 1999;83 (8):1220–1223.
  24. Sadoul N, Prasad K, Elliott PM et al. Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. Circulation. 1997;96 (9):2987–2991.
  25. Yu EH, Omran AS, Wigle ED et al. Mitral regurgitation in hypertrophic obstructive cardiomyopathy: Relationship to obstruction and relief with myectomy. J Am Coll Cardiol. 2000;36 (7):2219–2225.
  26. Zhu WX, Oh JK, Kopecky SL et al. Mitral regurgitation due to ruptured chordae tendineae in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 1992;20 (1):242–247.
  27. Panza JA, Petrone RK, Fananapazir L et al. Utility of continuous wave Doppler echocardiography in the noninvasive assessment of left ventricular outflow tract pressure gradient in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1992;19 (1):91–99.
  28. Kilicaslan F, Verma A, Saad E et al. Efficacy of catheter ablation of atrial fibrillation in patients with hypertrophic obstructive cardiomyopathy. Heart Rhythm. 2006;3 (3):275–280.
  29. Sherrid MV, Chaudhry FA, Swistel DG. Obstructive hypertrophic cardiomyopathy: Echocardiography, pathophysiology, and the continuing evolution of surgery for obstruction. Ann Thorac Surg. 2003;75 (2):620–632.
  30. Cape EG, Simons D, Jimoh A et al. Chordal geometry determines the shape and extent of systolic anterior mitral motion: in vitro studies. J Am Coll Cardiol. 1989;13 (6):1438–1448.
  31. Sasson Z, Yock PG, Hatle LK et al. Doppler echocardiographic determination of the pressure gradient in hypertrophic cardiomyo­pathy. J Am Coll Cardiol. 1988;11 (4):752–756.
  32. Shah PM, Taylor RD, Wong M et al. Abnormal mitral valve coaptation in Hypertrophic obstructive cardiomiopathy: proposed role of systolic anterior motion of mitral valve. Am J Cardiol. 1981;48 (2):258–262.
  33. Sherrid MV, Gunsburg DZ, Moldenhauer S, Pearle G. Systolic anterior motion begins at low left ventricular outflow tract velo­city in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2000;36 (4):1344–1354.
  34. Falicov RE, Resnekov L, Bharati S, et al. Mid-ventricular obstruction: a variant of obstructive cardiomyopathy. Am J Cardiol. 1976
  35. Maron BJ, Nishimura RA, Danielson GK. Pitfalls in clinical recognition and a novel operative approach for hypertrophic cardiomyopathy with severe outflow obstruction due to anomalous papillary muscle. Circulation. 1998;98 (23):2505–2508.
  36. Geske JB, Sorajja P, Ommen SR, Nishimura RA. Left ventricular outflow tract gradient variability in hypertrophic cardiomyopathy. Clin Cardiol. 2009;32 (7):397–402.
  37. Maron MS, Oliviotto I, Betocchi S et al. Effect of left ventricular outflow tract obstruction on clinical outcome in Hypertrophic cardiomiopathy. N Engl J Med. 2003;348 (4):295–303.
  38. Elesber A, Nishimura RA, Rihal CS et al. Utility of isoproterenol to provoke outflow tract gradients in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2008;101 (4):516–520.
  39. Gwathmey JK, Warren SE, Briggs GM et al Diastolic dysfunction in hypertrophic cardiomyopathy. Effect on active force generation during systole. J Clin Invest. 1991;87 (3):1023–1031.
  40. Betocchi S, Hess OM, Losi MA et al. Regional left ventricular mechanics in hypertrophic cardiomyopathy. Circulation. 1993;88 (5 Pt 1):2206–2214.
  41. Betocchi S, Piscione F, Villari В et al. Effects of induced asynchrony on left ventricular diastolic function in patients with coronary artery disease. J Am Coll Cardiol. 1993;21 (5):1124–1131.
  42. Bonow RO, Dilsizian V, Rosing DR et al. Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: short- and long-term effects. Circulation. 1985;72 (4):853–864.
  43. Spirito P, Maron BJ. Relation between extent of left ventricular hypertrophy and diastolic filling abnormalities in hypertrophic cardiomyopathy. J Am Coll Cardiol. 1990;15 (4):808–813.
  44. Мarian AJ. Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy. Lancet. 2000;355 (9197):58–60.
  45. Cannon RO III, Rosing DR, Maron BJ et al. Myocardial ischemia in patients with hypertrophic cardiomyopathy: contribution of inade­quate vasodilator reserve and elevated left ventricular filling pressures. Circulation. 1985;71 (2):234–243.
  46. Maron MS, Olivotto I, Maron BJ et al. The case for myocardial ische­mia in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2009;54 (9):866–875.
  47. Krams R, Kofflard MJ, Duncker DJ et al. Decreased coronary flow reserve in hypertrophic cardiomyopathy is related to remodelling of the coronary microcirculation. Circulation. 1998;97 (3):230–233.
  48. Maron BJ, Wolfson JK, Epstein SE, Roberts WC. Intramural ('small vessel') coronary ar-tery disease in hypertrophic cardiomyopathy. J Am Coll Cardiol. 1986;8 (3):545–557.
  49. Tanaka M, Fujiwara H, Onodera Т et al. Quantitative analysis of narrowing of intramyo-cardial small arteries in normal hearts, hypertensive hearts, and hearts with hypertrophic cardiomyopathy. Circulation. 1987;75 (6):1130–1139.
  50. Shirani J, Pick R, Roberts WC, Maron BJ. Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. J Am Coll Cardiol. 2000;35 (1):36–44.
  51. Olivotto I, Maron BJ, Montereggi A et al. Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1999;33 (7):2044–2051.
  52. Eckberg DL, Sleight P. Human Baroreflexes in Health and Disease. – New York: Oxford University Press, 1992; 43:79–119;
  53. Briguori C, Betocchi S, Manganelli F et al. Determinants and clinical significance of natriuretic peptides and hypertrophic cardiomyopathy. Eur Heart J. 2001;22 (15):1328–1336.
  54. Cannan CR, Reeder GS, Bailey KR et al. Natural history of hypertrophic cardiomyopathy: a population-based study, 1976 through 1990. Circulation. 1995;92 (9):2488–2495.
  55. Spirito P, Chiarella F, Carratino L et al. Clinical course and prognosis of hypertrophic cardiomyopathy in an outpatient population. N Engl J Med. 1989;320 (12):749–755.
  56. Elliott PM, Poloniecki J, Dickie S et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol. 2000;36 (7):2212–2218.
  57. Elliott PM, Gimeno Blanes JR, Mahon NG et al. Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet. 2001;357 (9254):420–424.
  58. Criley JM. Unobstructed thinking (and terminology) is called for in the understanding and management of hypertrophic cardiomyo­pathy. J Am Coll Cardiol. 1997;29 (4):741–743.
  59. Sorajja P, Valeti U, Nishimura RA et al. Outcome of alcohol septal ablation for obstructive hypertrophic cardiomiopathy. Circulation. 2008;118 (2):131–139.
  60. Bunch TJ, Munger TM, Friedman PA et al. Substrate and procedural predictors of outcomes after catheter ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol. 2008;19 (10):1009–1014.
Kaplunova V. Yu., Belenkov Yu. N., Privalova E. V. et al. Issues of etiology, pathophysiology and variants of hypertrophic cardiomyopathy course. Russian Heart Failure Journal. 2013;14 (3):141-148

To access this material please log in or register

Register Authorize
Ru En